5e5 of anti-CD7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HP2H6) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 1-2 ng/mL (QC tested).
The purity of Biotinylated Human CD7, Fc,Avitag(Cat. No. CD7-H82F3) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| GC-027 | GC-027 | Phase 1 Clinical | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD7 CAR-T cell Therapy (Shanghai General Hospital) | Phase 1 Clinical | Shanghai General Hospital | Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell | Details | |
| PA3-17 | PA3-17; PA-3-17; PA3-17 (autologous) | Phase 1 Clinical | Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| SenL-T7 CAR T Cells (Hebei Senlang Biological) | Senl-T7; Senl-T-7; SENL-101 | Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| This CAR-T-7 cells therapy | This CAR-T-7 cells | Fundamenta Therapeutics Ltd | Details | ||
| GC-502 | GC-502 | Details | |||
| Anti-CD7 universal CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Xinqiao Hospital, Army Medical University | Lymphoma, T-Cell; Leukemia, T-Cell | Details | |
| CD7-CAR-T cell therapy (PersonGen Biomedicine) | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University | Leukemia; Enteropathy-Associated T-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic | Details | |
| CAR7-T Cell Therapy (Beijing Gaobo Biotechnology Co Ltd) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, T-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Humanized CD7 CAR-T cells | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma, T-Cell | Details | |
| CD7 CAR-T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD7 CAR T-cell therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Still's Disease, Adult-Onset; Leukemia; Dermatomyositis; Autoimmune Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Colitis, Ulcerative; Lymphoma; Crohn Disease | Details | |
| Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics) | BT-007 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, Bioceltech Therapeutics Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| WU-CART-007 | WU-CART-007 | Phase 2 Clinical | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Leukemia-Lymphoma, Adult T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
| CD7 CARvac T cell therapy | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
| CD7 targeted CAR-γδ T cells therapy(Persongen Bio) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Neoplasms; Leukemia, B-Cell | Details | |
| RD13-01 | RD13-01; CTD-401 | Clinical | Zhejiang University, Nanjing Bioheng Biotech Co Ltd | Hematologic Neoplasms | Details |
| Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate | HENO-3; SPV-T3a | Phase 3 Clinical | Xenikos Bv | Graft vs Host Disease | Details |
| BEAM-201 | BEAM-201 | Phase 1 Clinical | Beam Therapeutics Inc | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
